Introduction
Discovery of Helicobacter pylori has changed the socalled "natural" history of peptic ulcer disease (PUD). Many investigators have reported that the cure of H. pylori infection almost completely prevents the recurrence of peptic ulcers, which was thought to be a destiny of this disease in the past. This evidence may be overestimated and the majority of gastroenterologists follow the new slogan: "no Helicobacter, no ulcer". Is it real that PUD disappears after the elimination of H. pylori? Some ulcers recur even after successful eradication of H. pylori in non-users of nonsteroidal anti-inflammatory drug (NSAID). In addition, incidence of H. pylori-negative, non-NSAID PUD (idiopathic PUD) is reported to be high in children and young adults, which may cause an increase in number of such an ulcer overtime. Taken together, H. pylori is not the only cause of peptic ulcer disease. The important point is whether the number of idiopathic PUD is negligible or not. If not, it is still necessary to seriously consider the pathophysiology and management of the ulcers, which may exist after elimination of H. pylori.
Is H. pylori Really a Cause of PUD?
It is a fact that the interventional treatment, eradication of H. pylori, results in a decrease in the recurrence of PUD. This is, however, not a proof of causative effect of this microorganism in the occurrence of the original ulcer. Boulos et al (1) demonstrated that all H. pylori-positive patients with duodenal ulcer had symptoms of more than 6 months while all, H. pylori-negative patients gave a history of less than 6 months. This report suggests that the infection occurs after development of the ulcer, and if so, it is not possible for H. pylori to cause ulcer formation. Most subjects positive for H. pylori do not have ulcer disease, also suggesting a lesser possibility of causative effect of H. pylori in ulcer formation.
Is Non-H. pylori, Non-NSAID Ulcer Really Rare?
H. pylori-negative duodenal ulcer was only rare by 2.8-6.0% in developed countries in the early 1990's (Table 1) (2, 3) , approximately half of these were NSAID-associated ulcers. Therefore, idiopathic duodenal ulcers, which are not associated with H. pylori or NSAIDs, were extremely rare at 0.3-1.4% (2, 3) . Recent studies have shown a higher incidence of idiopathic duodenal ulcers in USA and Australia, while the incidence of such an ulcer is still reportedly low in other countries, including Japan (Table 2) . From these results, idiopathic PUD has been thought to be increasing over time. This phenomenon may be, in part, due to the decrease in prevalence of H. pylori infection in the general population with time. In Japan, the incidence of idiopathic duodenal ulcers is much higher in children and young adults than in elderly people (Table 3 ) (4). This may be related to the unique phenomenon that the prevalence of H. pylori infection is 10-30% in the general population aged less than forty and around 80% in those over forty (5) .
The relatively high incidence of H. pylori-negative gastric ulcer is mainly due to NSAID use (Table 1) (3). In our hospital, H. pylori-negative gastric ulcer is as rare (2.5%) as H. pylori-negative duodenal ulcer (6). This low incidence of H. pylori-negative gastric ulcer may be due to the high prevalence rate of H. pylori infection in the general population in Japan. In other words, coincidental infection with this microorganism may exist in such patients regardless of ulcer disease. In addition, NSAID users are extremely rare in patients with H. pylori-negative gastric or duodenal ulcer. Most Japanese do not take NSAIDs on their own without consulting a physician. This custom may be a reason.
H. pylori-positive PUD is Not Always
H. pylori-related PUD Although H. pylori-negative ulcers are increasing, the majority of the ulcer patients are infected with this microorganism. However, among the H. pylori-positive patients, there are two paradoxes of the H. pylori myth: the existence of H. pylori-positive non-recurring ulcer and recurring ulcer after the cure of H. pylori infection (Fig. 1) . Therefore, the number of H. pylori-related ulcers must be much less than that of H. pylori-positive ulcer. This may lead us to the concept that there are two different types of infection with H. pylori: one is, of course, as a criminal and the other is as an innocent bystander (6).
Laine et al (7) recently reported that approximately 20% (33 cases out of 168) of duodenal ulcers recur six months after successful eradication of H. pylori in the study of metaanalysis of seven rigorously designed trials (Table 4) . These recurring ulcers after cure of H. pylori infection are used to be positive for H. pylori. Therefore, H. pylori which is infecting these patients is an innocent bystander. Their analysis also showed the recurrence of ulcer from H. pylori-positive patients at 56% (202 cases out of 363). This means that 44% (161 cases out of 363) of H. pylori-positive patients maintain remission. Therefore, in 37% (33 plus 161 cases out of 168 (8) showed similar results in their 7-year follow-up study in patients with duodenal ulcer. Their study was designed to examine mainly symptomatic recurrence. Therefore, endoscopic recurrence did not include asymptomatic recurrence. However, the ulcer recurred by 11% (4 cases out of 38) of the patients who were cured from H. pylori infection after the eradication therapy. On the other hand, the ulcer did not recur in 44% (14 cases out of 26) of the patients who were still positive for H. pylori after the eradication therapy. Therefore, H. pylori-non-causing duodenal ulcer also exists in 28% in such a long-term study. Our results of a 1-5 year follow-up study on gastric and duodenal ulcer after the eradication therapy also showed similar percentages of H. pylori-non-causing ulcer among H. pyloripositive ulcers (6) . A recent meta-analysis study, after 12 months of successful eradication, showed a relatively small recurrence rate of 3% (8 out of 274) in gastric ulcer patients and 2% (14 out of 683) in duodenal ulcer patients (9) . In this study the remission rate of gastric and duodenal ulcers is approximately 40% after 12 months of failure of eradication or no eradication therapy. The data indicate that 14% of gastric ulcer and 10% of duodenal ulcer are not concerned with H. pylori. All of these studies exclude NSAID ulcers. Moreover, the incidence of recurring ulcers constantly and linearly increases with time year by year. Therefore the findings indicate that H. pylori-non-causing ulcer is common in non-NSAID users. In these cases, H. pylori is not a pathogen but an opportunist (10) . Eradication therapy of H. pylori is an over treatment for these cases.
Concept of Quality of Ulcer Healing (QOUH)
In our previous study (11) , the quality of gastric ulcer healing as assessed by dye-contrast endoscopy can predict future ulcer recurrence. Ulcer recurrence from a non-flat, nodular scar is 100%, while only 20% of ulcers recur from a flat scar (12) . The nodular scar is characterized first by low prostaglandin production and secondly, high H. pylori infection compared with a flat scar (12) . Cure of H. pylori infection increases the ratio of flat scars, but non-flat scars still remain (13) . Prostaglandin deficiency may exist in these non-flat scars, which may be related to H. pylori-negative gastric ulcer. A prostaglandin-inducer, rebamipide, also increases the ratio of flat scars (13) , supporting that the deficiency of prostaglandins may cause poor gastric ulcer healing. Therefore, prostaglandin deficiency is at least one factor in H. pylori-negative gastric ulcer. Regarding H. pylori-negative duodenal ulcer, hyperacid secretion may be a specific feature (14) . Thus, we can barely see a small shadow of H. pylori-negative peptic ulcer disease. Further study is necessary to clarify the characteristics of such an ulcer.
Should H. pylori Be Eradicated in NSAID Users?
Most clinical studies indicate the independence of H. pylori and NSAIDs as risk factors of gastroduodenal mucosal injury, concluding that H. pylori infection is not a necessary underlying condition to gastric mucosal damage caused by NSAIDs (15) (16) (17) (18) (19) (20) (21) . Conversely, some studies have demonstrated that eradication of H. pylori reduces the rate of rebleeding in patients with peptic ulcer (22, 23) . A prospective study has also shown that eradication of H. pylori reduces the occurrence of mucosal injury caused by NSAIDs in arthritis patients (24) . A recent case-controled study in elderly has shown that H. pylori-positive NSAID users have a lower risk for gastrointestinal bleeding than H. pylorinegative NSAID users (21) . In both bleeding and nonbleeding groups assessed by symptoms and endoscopic examination, 47% of patients were affected with gastric ulcer, 37% with duodenal ulcer, and 16% with erosive gastritis (total 146 patients). NSAID use was significantly related to an increased risk of bleeding both in patients with gastric lesions (odds ratio: 4.98) and in those with duodenal ulcer (odds ratio: 10.2). In contrast, H. pylori-positivity presented a significant inverse relationship with bleeding in patients with gastric lesions (odds ratio: 0.20) and also in patients with duodenal ulcer (odds ratio: 0.39). The all over risk of bleeding in patients with gastric lesions was 0.99 and with duodenal ulcer was 3.97 in H. pylori-positive NSAID users, which was significantly less than in H. pylori-negative NSAID users. Additionally, H. pylori-negative arthritis patients receiving chronic NSAID therapy had significantly more frequent gastric mucosal hemorrhages than H. pyloripositive patients (15, 16) .
The mechanism for this protective effect of H. pylori infection is not known. Concentrations of gastric mucosal prostaglandin E2 are greater in H. pylori-positive patients than in H. pylori-negative patients (25, 26) , suggesting the involvement of endogenous prostaglandins in the mechanism. In chronic NSAID users, prostaglandin E2 generation in gastric mucosa is significantly higher in H. pylori-positive subjects (median value: 37.5 pg/mg) than in H. pylorinegative subjects (12.6 pg/mg) (27) . Therefore, H. pylori infection may attenuate the suppression of gastric mucosal prostaglandin generation associated with NSAID intake.
Meta-analysis has shown that the overall risk of the rebleeding is higher in H. pylori-positive than patients negative (28) . However, nothing may change in these patients even after cure of H. pylori infection, because the therapy for preventing the possible mucosal injury can not be neglected as long as NSAIDs are given. As for the healing of NSAIDulcers, eradication of H. pylori delays ulcer healing when treated with omeprazole (29) . Therefore, the eradication therapy should not be done if NSAID-ulcer is in an active stage, which needs conventional anti-ulcer treatment.
